The pharmaceutical field is experiencing a significant shift in blood sugar therapy with the arrival of GLP-1 transdermal devices. These revolutionary vehicles offer a likely simple option to subcutaneous injections for individuals managing diabetes mellitus type 2. By bypassing the requirement f